




RealRate

# PHARMACEUTICAL 2020

Intra Cellular Therapies Inc  
Rank 129 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Intra Cellular Therapies Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intra Cellular Therapies Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 87% points. The greatest weakness of Intra Cellular Therapies Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 289%, being 51% points above the market average of 238%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 230,324              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 36,224               |
| Liabilities, Non-Current                    | 19,955               |
| Other Assets                                | 18,603               |
| Other Compr. Net Income                     | 796                  |
| Other Expenses                              | 1.6                  |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 6,291                |
| Other Revenues                              | 61                   |
| Property and Equipment                      | 2,260                |
| Research and Development                    | 89,125               |
| Selling, General and Administrative Expense | 64,948               |

| Output Variable              | Value in<br>1000 USD |
|------------------------------|----------------------|
| Assets                       | 251,186              |
| Liabilities                  | 56,179               |
| Expenses                     | 154,074              |
| Revenues                     | 61                   |
| Stockholders Equity          | 195,007              |
| Net Income                   | -147,722             |
| Comprehensive Net Income     | -147,324             |
| BaseVar                      | 234,294              |
| ECR before Limited Liability | 181%                 |
| Economic Capital Ratio       | 289%                 |